The FDA and EMA on Pfizer’s Talazoparib
On June 7, Pfizer (PFE) announced that the FDA and the European Medicines Agency (or EMA) provided updates on the regulatory submissions of Talazoparib for the treatment of locally advanced or metastatic breast cancer. In this article, we’ll examine the drug, regulatory submissions, and clinical trials related to the drug.